Amgen Adopts Plan to Hamper Hostile Takeovers
Amgen, the Thousand Oaks biotechnology company, last week adopted a so-called “poison pill” provision that would make it more difficult for someone to acquire the company. Among other things, if someone acquires 20% or more of Amgen’s stock, it would allow Amgen’s other shareholders to buy additional Amgen stock at a 50% discount.
Amgen has several biotechnology drugs under development and is awaiting U.S. Food and Drug Administration approval to sell its anti-anemia drug.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
